Press "Enter" to skip to content

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab) – BioSpace

admin 0

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)  BioSpace
“skin cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *